<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1012-2966</journal-id>
<journal-title><![CDATA[Gaceta Médica Boliviana]]></journal-title>
<abbrev-journal-title><![CDATA[Gac Med Bol]]></abbrev-journal-title>
<issn>1012-2966</issn>
<publisher>
<publisher-name><![CDATA[Facultad de Medicina de la Universidad Mayor de San Simón]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1012-29662022000200142</article-id>
<article-id pub-id-type="doi">10.47993/gmb.v45i2.73</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Linfomas asociados a infección por el virus de inmunodeficiencia humana]]></article-title>
<article-title xml:lang="en"><![CDATA[Lymphomas associated with human immunodeficiency virus infection]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nina Garcia]]></surname>
<given-names><![CDATA[Nelson Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cabrera Aguilar]]></surname>
<given-names><![CDATA[Wendy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Caja Nacional de Salud Hospital de Especialidades Materno Infantil Servicio de Hematología]]></institution>
<addr-line><![CDATA[La Paz ]]></addr-line>
<country>Bolivia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<volume>45</volume>
<numero>2</numero>
<fpage>142</fpage>
<lpage>146</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S1012-29662022000200142&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S1012-29662022000200142&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S1012-29662022000200142&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivos: describir el perfil clínico y resultados del tratamiento de casos de Linfoma asociado a infección por el Virus de Inmunodeficiencia Humana.  Métodos: estudio retrospectivo de casos de linfoma asociado a infección por el Virus de Inmunodeficiencia Humana, atendidos en el servicio de Hematología del Hospital Materno Infantil, La Paz, Bolivia durante el periodo 2010-2021.  Resultados: se estudiaron ocho casos, de los cuales 6 (75%) eran del sexo masculino. En relación a la edad, la media fue de 40,75 años. 7 (87,5%) eran Linfoma no Hodgkin y un caso a Linfoma de Hodgkin. En siete pacientes el diagnóstico de linfoma fué posterior a la detección de la infección por el Virus de Inmunodeficiencia Humana, con un tiempo medio de 4,6 años. El 75% de los casos se presentaron con un estadio avanzado. De los siete casos de Linfoma no Hodgkin, cinco correspondían al Linfoma Difuso de Células Grandes B. El tratamiento quimioterápico se inició en todos los casos pero solo tres completaron los ciclos programados, el restante dejaron el tratamiento principalmente debido a complicaciones infecciosas. Se registraron cuatro (50%) fallecimientos, de los cuales tres ocurrieron en los primeros cuatro meses desde el diagnóstico de linfoma.  Conclusiones: en el presente estudio, el Linfoma no Hodgkin fue el más frecuente, representado principalmente por el Linfoma Difuso de Células Grandes B. Una característica común fue la presentación en estadios avanzados. La quimioterapia no se pudo completar en la mayoría de los casos debido a complicaciones relacionadas con la inmunodepresión, la mitad de los casos fallecieron durante el periodo de estudio.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objectives: to describe the clinical profile and treatment outcomes of cases of lymphoma associated with Human Immunodeficiency Virus infection.  Methods: retrospective study of cases of lymphoma associated with Human Immunodeficiency Virus infection treated at the Hematology Department of the Materno Infantil Hospital, La Paz, Bolivia during the period 2010-2021.  Results: Eight cases were studied, of which 6 (75%) were male. The mean age was 40.75 years. 7 (87.5%) were Non-Hodgkin's Lymphoma and one case was Hodgkin's Lymphoma. In seven patients, the diagnosis of lymphoma was made after the detection of Human Immunodeficiency Virus infection, with a mean time of 4.6 years. 75% of the cases presented with advanced stage. Of the seven cases of Non-Hodgkin's Lymphoma, five corresponded to Large B-Cell Lymphoma. Chemotherapy was started in all cases but only three completed the scheduled cycles, the remainder stopped treatment mainly due to infectious complications. Four (50%) deaths were recorded, three of which occurred within the first four months after the diagnosis of lymphoma.  Conclusions: In this study, Non-Hodgkin's Lymphoma was the most frequent, represented mainly by Large B-Cell Lymphoma. A common characteristic was the presentation at advanced stages. Chemotherapy could not be completed in the majority of cases due to complications related to immunodepression, and half of the cases died during the study period.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[linfoma]]></kwd>
<kwd lng="es"><![CDATA[VIH]]></kwd>
<kwd lng="es"><![CDATA[SIDA]]></kwd>
<kwd lng="es"><![CDATA[tratamiento antirretroviral]]></kwd>
<kwd lng="es"><![CDATA[Bolivia]]></kwd>
<kwd lng="en"><![CDATA[Lymphoma]]></kwd>
<kwd lng="en"><![CDATA[HIV]]></kwd>
<kwd lng="en"><![CDATA[AIDS]]></kwd>
<kwd lng="en"><![CDATA[antiretroviral therapy]]></kwd>
<kwd lng="en"><![CDATA[Bolivia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shiels]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Engels]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolving epidemiology of HIV-associated malignancies]]></article-title>
<source><![CDATA[Curr Opin HIV AIDS]]></source>
<year>2017</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6-11</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vangipuram]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tyring]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AIDS-Associated Malignancies]]></article-title>
<source><![CDATA[Cancer Treat Res]]></source>
<year>2019</year>
<volume>177</volume>
<page-range>1-21</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meister]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hentrich]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wyen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hübel]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant lymphoma in the HIV-positive patient]]></article-title>
<source><![CDATA[Eur J Haematol]]></source>
<year>2018</year>
<volume>101</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-126</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Re]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cattaneo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hiv and Lymphoma from Epidemiology to Clinical Management]]></article-title>
<source><![CDATA[Mediterr J Hematol Infect Dis]]></source>
<year>2019</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brunnberg]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Hentrich]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffmann]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hübel]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV-Associated Malignant Lymphoma]]></article-title>
<source><![CDATA[Oncol Res Treat]]></source>
<year>2017</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>82-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silas]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Achenbach]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hou]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcome of HIV-associated lymphoma in a resource-limited setting of Jos, Nigeria]]></article-title>
<source><![CDATA[Infect Agent Cancer]]></source>
<year>2017</year>
<volume>12</volume>
<page-range>34</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riedel]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rositch]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Redfield]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Blattner]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV-associated lymphoma sub-type distribution, immunophenotypes and survival in an urban clinic population]]></article-title>
<source><![CDATA[Leuk Lymphoma]]></source>
<year>2016</year>
<volume>57</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>306-12</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carroll]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Garzino-Demo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV-associated lymphoma in the era of combination antiretroviral therapy shifting the immunological landscape]]></article-title>
<source><![CDATA[Pathog Dis]]></source>
<year>2015</year>
<volume>73</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>ftv044</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Engels]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeiffer]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Landgren]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era]]></article-title>
<source><![CDATA[J Acquir Immune Defic Syndr]]></source>
<year>2010</year>
<volume>54</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>78-84</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sampath]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Manipadam]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Nair]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Viswabandya]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zachariah]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV-associated lymphoma A 5-year clinicopathologic study from India]]></article-title>
<source><![CDATA[Indian J Pathol Microbiol]]></source>
<year>2019</year>
<volume>62</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>73-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hulland]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy]]></article-title>
<source><![CDATA[Cancer Epidemiol Biomarkers Prev]]></source>
<year>2017</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>303-11</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical management of HIV-associated hematologic malignancies]]></article-title>
<source><![CDATA[Expert Rev Hematol]]></source>
<year>2016</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>361-76</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gopal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Yanik]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2013</year>
<volume>105</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1221-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Roselló]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV-related lymphoma in a public hospital in Chile. Analysis of 55 cases]]></article-title>
<source><![CDATA[Rev. méd. Chile.]]></source>
<year>2012</year>
<volume>140</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>243-50</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cuellar]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Anampa-Guzmán]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Holguín]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma a Peruvian experience]]></article-title>
<source><![CDATA[Infect Agent Cancer]]></source>
<year>2018</year>
<volume>13</volume>
<page-range>27</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sotomayor-Duque]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Colunga-Pedraza]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Colunga-Pedraza]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linfoma no Hodgkin e infección por el virus de la inmunodeficiencia humana Experiencia de 10 años en un centro de referencia universitario]]></article-title>
<source><![CDATA[Rev Hematol Mex]]></source>
<year>2017</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>155-60</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
